Literature DB >> 34455436

Hypermutated recurrences: Identifying the clinical relevance.

Marjolein Geurts1, Martin J van den Bent1.   

Abstract

Entities:  

Mesh:

Year:  2021        PMID: 34455436      PMCID: PMC8563306          DOI: 10.1093/neuonc/noab192

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   13.029


× No keyword cloud information.
  10 in total

1.  MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence.

Authors:  Radhika Mathur; Yalan Zhang; Matthew R Grimmer; Chibo Hong; Michael Zhang; Saumya Bollam; Kevin Petrecca; Jennifer Clarke; Mitchel S Berger; Joanna J Phillips; Nancy Ann Oberheim-Bush; Annette M Molinaro; Susan M Chang; Joseph F Costello
Journal:  Neuro Oncol       Date:  2020-11-26       Impact factor: 12.300

2.  Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma.

Authors:  Brett E Johnson; Tali Mazor; Chibo Hong; Michael Barnes; Koki Aihara; Cory Y McLean; Shaun D Fouse; Shogo Yamamoto; Hiroki Ueda; Kenji Tatsuno; Saurabh Asthana; Llewellyn E Jalbert; Sarah J Nelson; Andrew W Bollen; W Clay Gustafson; Elise Charron; William A Weiss; Ivan V Smirnov; Jun S Song; Adam B Olshen; Soonmee Cha; Yongjun Zhao; Richard A Moore; Andrew J Mungall; Steven J M Jones; Martin Hirst; Marco A Marra; Nobuhito Saito; Hiroyuki Aburatani; Akitake Mukasa; Mitchel S Berger; Susan M Chang; Barry S Taylor; Joseph F Costello
Journal:  Science       Date:  2013-12-12       Impact factor: 47.728

3.  Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment.

Authors:  Qianghu Wang; Baoli Hu; Xin Hu; Hoon Kim; Massimo Squatrito; Lisa Scarpace; Ana C deCarvalho; Sali Lyu; Pengping Li; Yan Li; Floris Barthel; Hee Jin Cho; Yu-Hsi Lin; Nikunj Satani; Emmanuel Martinez-Ledesma; Siyuan Zheng; Edward Chang; Charles-Etienne Gabriel Sauvé; Adriana Olar; Zheng D Lan; Gaetano Finocchiaro; Joanna J Phillips; Mitchel S Berger; Konrad R Gabrusiewicz; Guocan Wang; Eskil Eskilsson; Jian Hu; Tom Mikkelsen; Ronald A DePinho; Florian Muller; Amy B Heimberger; Erik P Sulman; Do-Hyun Nam; Roel G W Verhaak
Journal:  Cancer Cell       Date:  2018-01-08       Impact factor: 31.743

4.  Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813.

Authors:  Susan Chang; Peixin Zhang; J Gregory Cairncross; Mark R Gilbert; Jean-Paul Bahary; Carol A Dolinskas; Arnab Chakravarti; Kenneth D Aldape; Erica H Bell; David Schiff; Kurt Jaeckle; Paul D Brown; Geoffrey R Barger; Maria Werner-Wasik; Helen Shih; David Brachman; Marta Penas-Prado; H Ian Robins; Karl Belanger; Christopher Schultz; Grant Hunter; Minesh Mehta
Journal:  Neuro Oncol       Date:  2017-02-01       Impact factor: 12.300

5.  MGMT gene silencing and benefit from temozolomide in glioblastoma.

Authors:  Monika E Hegi; Annie-Claire Diserens; Thierry Gorlia; Marie-France Hamou; Nicolas de Tribolet; Michael Weller; Johan M Kros; Johannes A Hainfellner; Warren Mason; Luigi Mariani; Jacoline E C Bromberg; Peter Hau; René O Mirimanoff; J Gregory Cairncross; Robert C Janzer; Roger Stupp
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

6.  Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency.

Authors:  Eric Bouffet; Valérie Larouche; Brittany B Campbell; Daniele Merico; Richard de Borja; Melyssa Aronson; Carol Durno; Joerg Krueger; Vanja Cabric; Vijay Ramaswamy; Nataliya Zhukova; Gary Mason; Roula Farah; Samina Afzal; Michal Yalon; Gideon Rechavi; Vanan Magimairajan; Michael F Walsh; Shlomi Constantini; Rina Dvir; Ronit Elhasid; Alyssa Reddy; Michael Osborn; Michael Sullivan; Jordan Hansford; Andrew Dodgshun; Nancy Klauber-Demore; Lindsay Peterson; Sunil Patel; Scott Lindhorst; Jeffrey Atkinson; Zane Cohen; Rachel Laframboise; Peter Dirks; Michael Taylor; David Malkin; Steffen Albrecht; Roy W R Dudley; Nada Jabado; Cynthia E Hawkins; Adam Shlien; Uri Tabori
Journal:  J Clin Oncol       Date:  2016-03-21       Impact factor: 44.544

7.  Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study.

Authors:  Martin J van den Bent; C Mircea S Tesileanu; Wolfgang Wick; Marc Sanson; Alba Ariela Brandes; Paul M Clement; Sarah Erridge; Michael A Vogelbaum; Anna K Nowak; Jean Français Baurain; Warren P Mason; Helen Wheeler; Olivier L Chinot; Sanjeev Gill; Matthew Griffin; Leland Rogers; Walter Taal; Roberta Rudà; Michael Weller; Catherine McBain; Jaap Reijneveld; Roelien H Enting; Francesca Caparrotti; Thierry Lesimple; Susan Clenton; Anja Gijtenbeek; Elizabeth Lim; Ulrich Herrlinger; Peter Hau; Frederic Dhermain; Iris de Heer; Kenneth Aldape; Robert B Jenkins; Hendrikus Jan Dubbink; Johan M Kros; Pieter Wesseling; Sarah Nuyens; Vassilis Golfinopoulos; Thierry Gorlia; Pim French; Brigitta G Baumert
Journal:  Lancet Oncol       Date:  2021-05-14       Impact factor: 54.433

8.  Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas.

Authors:  Yao Yu; Javier Villanueva-Meyer; Matthew R Grimmer; Stephanie Hilz; David A Solomon; Serah Choi; Michael Wahl; Tali Mazor; Chibo Hong; Anny Shai; Joanna J Phillips; Bruce H Wainer; Michael McDermott; Daphne Haas-Kogan; Jennie W Taylor; Nicholas Butowski; Jennifer L Clarke; Mitchel S Berger; Annette M Molinaro; Susan M Chang; Joseph F Costello; Nancy Ann Oberheim Bush
Journal:  Neuro Oncol       Date:  2021-11-02       Impact factor: 13.029

9.  Mechanisms and therapeutic implications of hypermutation in gliomas.

Authors:  Mehdi Touat; Yvonne Y Li; Adam N Boynton; Liam F Spurr; J Bryan Iorgulescu; Craig L Bohrson; Isidro Cortes-Ciriano; Cristina Birzu; Jack E Geduldig; Kristine Pelton; Mary Jane Lim-Fat; Sangita Pal; Ruben Ferrer-Luna; Shakti H Ramkissoon; Frank Dubois; Charlotte Bellamy; Naomi Currimjee; Juliana Bonardi; Kenin Qian; Patricia Ho; Seth Malinowski; Leon Taquet; Robert E Jones; Aniket Shetty; Kin-Hoe Chow; Radwa Sharaf; Dean Pavlick; Lee A Albacker; Nadia Younan; Capucine Baldini; Maïté Verreault; Marine Giry; Erell Guillerm; Samy Ammari; Frédéric Beuvon; Karima Mokhtari; Agusti Alentorn; Caroline Dehais; Caroline Houillier; Florence Laigle-Donadey; Dimitri Psimaras; Eudocia Q Lee; Lakshmi Nayak; J Ricardo McFaline-Figueroa; Alexandre Carpentier; Philippe Cornu; Laurent Capelle; Bertrand Mathon; Jill S Barnholtz-Sloan; Arnab Chakravarti; Wenya Linda Bi; E Antonio Chiocca; Katie Pricola Fehnel; Sanda Alexandrescu; Susan N Chi; Daphne Haas-Kogan; Tracy T Batchelor; Garrett M Frampton; Brian M Alexander; Raymond Y Huang; Azra H Ligon; Florence Coulet; Jean-Yves Delattre; Khê Hoang-Xuan; David M Meredith; Sandro Santagata; Alex Duval; Marc Sanson; Andrew D Cherniack; Patrick Y Wen; David A Reardon; Aurélien Marabelle; Peter J Park; Ahmed Idbaih; Rameen Beroukhim; Pratiti Bandopadhayay; Franck Bielle; Keith L Ligon
Journal:  Nature       Date:  2020-04-15       Impact factor: 49.962

10.  Longitudinal molecular trajectories of diffuse glioma in adults.

Authors:  Floris P Barthel; Kevin C Johnson; Frederick S Varn; Anzhela D Moskalik; Georgette Tanner; Emre Kocakavuk; Kevin J Anderson; Olajide Abiola; Kenneth Aldape; Kristin D Alfaro; Donat Alpar; Samirkumar B Amin; David M Ashley; Pratiti Bandopadhayay; Jill S Barnholtz-Sloan; Rameen Beroukhim; Christoph Bock; Priscilla K Brastianos; Daniel J Brat; Andrew R Brodbelt; Alexander F Bruns; Ketan R Bulsara; Aruna Chakrabarty; Arnab Chakravarti; Jeffrey H Chuang; Elizabeth B Claus; Elizabeth J Cochran; Jennifer Connelly; Joseph F Costello; Gaetano Finocchiaro; Michael N Fletcher; Pim J French; Hui K Gan; Mark R Gilbert; Peter V Gould; Matthew R Grimmer; Antonio Iavarone; Azzam Ismail; Michael D Jenkinson; Mustafa Khasraw; Hoon Kim; Mathilde C M Kouwenhoven; Peter S LaViolette; Meihong Li; Peter Lichter; Keith L Ligon; Allison K Lowman; Tathiane M Malta; Tali Mazor; Kerrie L McDonald; Annette M Molinaro; Do-Hyun Nam; Naema Nayyar; Ho Keung Ng; Chew Yee Ngan; Simone P Niclou; Johanna M Niers; Houtan Noushmehr; Javad Noorbakhsh; D Ryan Ormond; Chul-Kee Park; Laila M Poisson; Raul Rabadan; Bernhard Radlwimmer; Ganesh Rao; Guido Reifenberger; Jason K Sa; Michael Schuster; Brian L Shaw; Susan C Short; Peter A Sillevis Smitt; Andrew E Sloan; Marion Smits; Hiromichi Suzuki; Ghazaleh Tabatabai; Erwin G Van Meir; Colin Watts; Michael Weller; Pieter Wesseling; Bart A Westerman; Georg Widhalm; Adelheid Woehrer; W K Alfred Yung; Gelareh Zadeh; Jason T Huse; John F De Groot; Lucy F Stead; Roel G W Verhaak
Journal:  Nature       Date:  2019-11-20       Impact factor: 69.504

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.